Spyre Therapeutics, Inc. Common Stock (SYRE) Financials
Key financial figures for Spyre Therapeutics, Inc. Common Stock (Q2 2026).
- Revenue
- $0
- Net Income
- -$36M
- Total Assets
- $1.2B
- Operating Cash Flow
- -$70M
Full income statement, balance sheet, and cash flow for Spyre Therapeutics, Inc. Common Stock on SentiSense.